Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020

} HONG KONG and FLORHAM PARK, N.J., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that new and updated analyses on the studies of surufatinib and fruquintinib will be presented at the upcoming European Society for Medical Oncology (ESMO) Virtual Congress 2020, taking place on September 17-21, 2020.Further details of the presentations are as follows: SURUFATINIB Title: Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumors (SANET-p): a randomized, double-blind, placebo (P)-controlled Phase III trial (NCT02589821) Lead Author: Jianming Xu, Head of the Department of Gastrointestinal Oncology, The Fifth Medical Center, General Hospital of the PLA Session: Proffered Paper - NETs Abstract #: 1156O Date & Time: Sunday, September 20, 2020 2:25 PM CEST Room: Channel 3     Title: Subgroup analysis by Ki-67 and primary tumor origins of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated extrapancreatic neuroendocrine tumors (SANET-ep) Lead Author: Zhiwei Zhou, Director, Department of Gastric and Pancreatic Surgery, Sun Yat-sen University Cancer Center Session: e-Poster Display Session Abstract #: 1165P Date available: Thursday, September 17, 2020 FRUQUINTINIB Title: Phase (Ph) 1/1b Trial of Fruquintinib (Fru) in Patients (Pts) with Advanced Solid Tumors: Preliminary Results of the To keep reading about Chi-Med Highlights Clinical Data to be Presented at the Upcoming ESMO Virtual Congress 2020, Click on the link. Seoul, Korea
http://dlvr.it/RfDBVT

Comments

Post a Comment

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Image
(RTTNews) - AstraZeneca Plc (AZN.L, AZN) said first participants have been dosed in a Phase I trial of AZD7442 for the prevention and treatment of COVID-19. The trial will evaluate the safety, tolerability and pharmacokinetics of AZD7442. It will include up to 48 healthy participants in the UK aged 18 to 55 years. AZD7442 is a combination of two monoclonal antibodies derived from convalescent patients with SARS-CoV-2 infection. Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the mAbs were optimised by AstraZeneca. Data readout from the trial is anticipated in the second half of 2020. To keep reading about AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts, Click on the link. Seoul, Korea http://dlvr.it/RfHgSK
Read more

7 lies to stop telling yourself if you want to become mentally stronger

Image
Crystal Cox/Business Insider Amy Morin is a psychotherapist, licensed clinical social worker, mental strength coach, and international bestselling author. She explains that sometimes our own thoughts can hold us back, especially if we tend to dwell on negative events, insecurities, and self-doubt. Morin says it's important to confront thoughts like "I'm not good enough" or "I'm too damaged," and replace them with self-empathy by instead saying "I am worth it" or "I'm a survivor." Visit Business Insider's homepage for more stories. Many of the things you tell yourself aren't true. And there's a good chance you've bought into some unhealthy beliefs over the years. Courtesy of Amy Morin In the therapy world, we call these "cognitive distortions." We all have them. Learning to recognize these lies we tell ourselves and replace them with healthier, more realistic statements is key to building mental str...
Read more